Company Overview
About VenoStent
VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.
Business Model & Competitive Advantage
VenoStent's SelfWrap perivascular device addresses the AV fistula failure rate that is the leading cause of hospitalization and morbidity in dialysis patients: an AV fistula (a surgical connection between an artery and vein in the forearm that creates a high-flow vascular access point for dialysis needle cannulation) fails to mature into a usable access in 20-60% of cases due to neointimal hyperplasia — the body's smooth muscle cell proliferation response to surgical trauma that narrows the vein and prevents adequate blood flow for dialysis. SelfWrap's bioabsorbable outer wrap (applied around the vein at the time of fistula creation, providing mechanical support and controlled drug delivery to modulate the healing response) is designed to reduce the hyperplasia cascade that causes fistula failure — improving the primary patency rates that determine whether a dialysis patient uses their own fistula or requires a catheter (which carries 3x higher infection risk and 2x higher mortality).
Competitive Landscape 2025–2026
In 2025, VenoStent competes in the hemodialysis vascular access, endovascular devices, and chronic kidney disease management market with Merit Medical (NASDAQ: MMSI, vascular access products, $1.2B revenue), BD (NYSE: BDX, hemodialysis catheter market leader, $20B revenue), and Vasc-Alert (AV access monitoring) for dialysis center and vascular surgery adoption of AV fistula maturation improvement devices. Good Growth Capital's Series A leadership and Norwest Venture Partners' participation reflect medtech venture conviction in vascular access innovation. NIH SBIR Phase II grant validation confirms scientific merit. Y Combinator W20 backing (unusual for a medical device company) connects VenoStent with the healthcare technology investor community. The 2025 strategy focuses on completing RCT enrollment across US dialysis and vascular surgery centers, building the clinical outcomes dataset for FDA De Novo or 510(k) submission, and engaging the dialysis network operators (DaVita, Fresenius) as commercial launch channels.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
VenoStent is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare VenoStent with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from VenoStent? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim VenoStent Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention VenoStent vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →